Wray, Sibyl
Then Bergh, Florian
Wundes, Annette
Arnold, Douglas L.
Drulovic, Jelena
Jasinska, Elzbieta
Bowen, James D.
Negroski, Donald
Naismith, Robert T.
Hunter, Samuel F.
Gudesblatt, Mark
Chen, Hailu
Lyons, Jennifer
Shankar, Sai L.
Kapadia, Shivani
Mendoza, Jason P.
Singer, Barry A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study
https://doi.org/10.1007/s40120-024-00637-2
Diroximel fumarate pregnancy outcomes in EVOLVE-MS-1 and prospective MS pregnancy exposure registry study design
https://doi.org/10.1136/jnnp-2023-abn.206
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study
https://doi.org/10.1007/s12325-022-02068-7
Article History
Received: 19 November 2021
Accepted: 7 December 2021
First Online: 24 February 2022